Lung cancer advances beyond PD1
Lung cancer advances beyond PD1
Identifying rare mutations in lung cancer
Lymphoma highlights from ASCO annual meeting 2017
New trial results and updates on CML, CLL and MDS
Targeting EGFR and ALK mutations
Abiraterone for metastatic, hormone sensitive, prostate cancer
New treatments for acute myeloid leukaemia and lymphoid leukaemia
Current and future prospects in treating multiple myeloma
New drug advancements presented at ASCO
Developing technologies and the field of oncology
The Bonnie J Addario Lung Cancer Foundation
Haematology advances in review
Changing the standard of care: Metastatic prostate cancer